Management

• Year of birth: 1964
• Nationality: Dutch
• Appointment: since February 2020, appointed until January 2027

Adriaan Moelker is a seasoned leader of global, innovation-driven businesses. Before joining BRAIN Biotech AG, he held a wide variety of management positions during his 30-year career, and his particular focus has been on Biotechnology. At AB Enzymes GmbH in Darmstadt, he was Managing Director for 9 years and during that time he directed the company to double-digit profit growth whilst building a strong business development pipeline. Previously, Adriaan had spent 12 years at Genencor (today DuPont) and DSM in the enzyme business, always focusing on business and innovation management. Consequently, he has extensive global experience in all key industrial enzyme segments: Food, Feed and Technical. For the past 6 years, he ran a printing solutions business for Flint Group, where he implemented substantial strategic change and accelerated the innovation pipeline.

Adriaan holds an MBA and a bachelor’s degree from Nyenrode University in the Netherlands and has completed Executive Education modules at INSEAD, Fontainebleau (France) as well as at Harvard Business School, Boston (USA).

Adriaan Moelker was appointed as Chief Executive Officer (CEO) of BRAIN Biotech AG with effect from February 01, 2020.

• Year of birth: 1970
• Nationality: Deutsch
• Appointment: since October 2022, appointed until September 2025

Michael Schneiders has more than twenty years of experience in the capital market with a strong focus on German equities and international institutional investors. Prior to his employment at BRAIN, Michael held a variety of management positions in investment banking, including Head of Equities & Research. He was also involved in the IPO of BRAIN.

Michael studied Business Administration with a focus on finance and marketing at the University of Siegen, Germany, and Economics at the University of Redlands, US. In addition, he completed several executive education modules in the US at the Kellogg School of Management and the University of Chicago.

In Mai 2020, Michael joined former BRAIN AG as Head of Investor Relations and later became, in addition, the Head of Sustainability. BRAIN Biotech AG appointed Michael Schneiders as Chief Financial Officer (CFO) to the executive management board with effect from October 1st, 2022.

Rod Sears Black is CEO of Biocatalysts Ltd, based in Cardiff, Wales, UK.

Contact 

LinkedIn

Biocatalysts Cardiff Site: 

Biocatalysts Ltd.
Unit 1, Cefn Coed,
Parc Nantgarw, Cardiff
CF15 7QQ
Wales, UK
www.biocatalysts.com

• Has been with Breatec BV, the specialist in bakery enzymes, for more than 13 years.
• Experienced international operations leader, dedicated to enhancing efficiency and delivering results within the food and biotech sectors.
• Background encompasses a broad range of expertise, including operations management, sales, procurement, and production, with a strong emphasis on Lean Six Sigma and continuous improvement.

Contact

LinkedIn

Biocatalysts "Baking" site, Netherlands:

BREATEC B.V.
Vimmerik 2M
5253 CB Nieuwkuijk
The Netherlands

E-Mail Biocatalysts Baking

Contact

Biocatalysts "Beverages" site, Germany:

WeissBioTech GmbH
Max-Planck-Straße 16A
64572 Büttelborn
Germany
E-Mail

Ludwig has been Vice President USA for Biocatalysts Ltd. since 2024.

• Born in 1987
• Studied Molecular Biotechnology at the TU Munich
• Doctorate at the Chair of Bioprocess Engineering at the TU Munich

Ludwig in the BRAIN Biotech Group:

• 2018: Project Manager Enzyme Development, BRAIN Biotech Zwingenberg
• 2020: Head of Product Development, WeissBioTech
• 2021: Managing Director WeissBioTech / Responsible as Global Technical & Marketing Director Baking & Beverages
• 2024: Vice President USA, Biocatalysts

Contact Us

LinkedIn

Location Biocatalysts USA:
Biosun Biochemicals Inc.
Benjamin Rd Ste 600, Tampa, FL 33634, USA
Email to Biocatalysts USA

Dr. Martin Langer begleitet BRAIN Biotech seit 1995, hatte seitdem viele unterschiedliche Positionen inne und und ist heute Managing Director für das BioScience-Geschäfts am Standort Zwingenberg.

• Born 1965
• Biochemist and molecular biologist
• Studied biology at the Technical University of Darmstadt, at Adelaide University, Australia, and at University of Karlsruhe
• Doctoral thesis on enzymes with rare prosthetic groups and their catalytic behavior (University of Karlsruhe)

Martin Langer at BRAIN Biotech

• 1995: Project Manager
• 1999 - 2005: worked for VISCUM, a company spun off from BRAIN
• 2005: Head of Corporate Development Unit
• 2013: Appointment to the management of BRAIN Biotech AG
• 2015: Head of the IPO team at BRAIN
• 2016 - 2018: Responsible for Investor Relations in addition to Head of Corporate Development
• 2018 - 2020: Responsibility for the Industrial BioSolutions business unit
• 2020: Head of Business Development; responsibility for New Business Development business and for TMS business
• 2023: Managing Director BioScience Operations Zwingenberg

contact

LinkedIn

Operation site BRAIN Biotech Zwingenberg: 

BRAIN Biotech AG
Darmstädter Straße 34 - 36
64673 Zwingenberg
Germany
Website BRAIN Biotech Zwingenberg

Lutz is currently Managing Director at AnalytiCon Discovery, a BioScience division of BRAIN Biotech AG.

Previously:

• Studied chemistry in Berlin (Technical University)
• Doctorate in natural product chemistry in 1985
• Founder and co-founder of several life science companies, including AnalytiCon AG (natural products), Noxxon Pharma (RNA therapeutics), Sepiatec (separation technologies), Biotecon (protein-based therapeutics, PCR diagnostics) and AnalytiCon Discovery
• 1995 to 2024: CEO of AnalytiCon AG and since 2000 CEO of AnalytiCon Discovery GmbH

contact

LinkedIn

Operation site AnalytiCon Discovery:

Hermannswerder Haus 17
14473 Potsdam
Germany
Website